CL2016002368A1 - Compounds derived from benzamide, inhibitors of wnt signaling pathways; intermediary compounds; compositions and pharmacological combinations; useful for the prevention or treatment of polyposis coli, osteoporosispseudoglioma syndrome, exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra amelia syndrome, type 2 diabetes mellitus, fragile syndrome, solid tumors, among others. - Google Patents

Compounds derived from benzamide, inhibitors of wnt signaling pathways; intermediary compounds; compositions and pharmacological combinations; useful for the prevention or treatment of polyposis coli, osteoporosispseudoglioma syndrome, exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra amelia syndrome, type 2 diabetes mellitus, fragile syndrome, solid tumors, among others.

Info

Publication number
CL2016002368A1
CL2016002368A1 CL2016002368A CL2016002368A CL2016002368A1 CL 2016002368 A1 CL2016002368 A1 CL 2016002368A1 CL 2016002368 A CL2016002368 A CL 2016002368A CL 2016002368 A CL2016002368 A CL 2016002368A CL 2016002368 A1 CL2016002368 A1 CL 2016002368A1
Authority
CL
Chile
Prior art keywords
syndrome
compounds
benzamide
tetra
inhibitors
Prior art date
Application number
CL2016002368A
Other languages
Spanish (es)
Inventor
Kai Thede
Eckhard Bender
William Scott
Anja Giese
Ludwig Zorn
Ningshu Liu
Ursula Mönning
Franziska Siegel
Stefan Golz
Andrea Hägebarth
Philip Lienau
Florian Puehler
Daniel Basting
Dirk Schneider
Manfred Möwes
Jens Geisler
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CL2016002368A1 publication Critical patent/CL2016002368A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos derivados de benzamida, inhibidores de las vías de señalización de WNT; compuestos intermediarios; composiciones y combinaciones farmacológicas; útiles para la prevención o tratamiento de poliposis coli, síndrome de osteoporosispseudoglioma, vitreorretinopatía exudativa, angiogénesis retinal, enfermedad coronaria temprana, síndrome tetra Amelia, diabetes mellitus tipo 2, síndrome de frágil, tumores sólidos, entre otras.Compounds derived from benzamide, inhibitors of WNT signaling pathways; intermediary compounds; compositions and pharmacological combinations; useful for the prevention or treatment of polyposis coli, osteoporosispseudoglioma syndrome, exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra Amelia syndrome, type 2 diabetes mellitus, fragile syndrome, solid tumors, among others.

CL2016002368A 2014-03-20 2016-09-20 Compounds derived from benzamide, inhibitors of wnt signaling pathways; intermediary compounds; compositions and pharmacological combinations; useful for the prevention or treatment of polyposis coli, osteoporosispseudoglioma syndrome, exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra amelia syndrome, type 2 diabetes mellitus, fragile syndrome, solid tumors, among others. CL2016002368A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461968172P 2014-03-20 2014-03-20
EP14185274 2014-09-18

Publications (1)

Publication Number Publication Date
CL2016002368A1 true CL2016002368A1 (en) 2017-03-03

Family

ID=65628886

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002368A CL2016002368A1 (en) 2014-03-20 2016-09-20 Compounds derived from benzamide, inhibitors of wnt signaling pathways; intermediary compounds; compositions and pharmacological combinations; useful for the prevention or treatment of polyposis coli, osteoporosispseudoglioma syndrome, exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra amelia syndrome, type 2 diabetes mellitus, fragile syndrome, solid tumors, among others.

Country Status (5)

Country Link
CL (1) CL2016002368A1 (en)
IL (1) IL247327A0 (en)
MA (1) MA39762A (en)
SV (1) SV2016005282A (en)
ZA (1) ZA201605726B (en)

Also Published As

Publication number Publication date
MA39762A (en) 2017-01-25
ZA201605726B (en) 2019-11-27
SV2016005282A (en) 2018-12-05
IL247327A0 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
CO2019000386A2 (en) Heterocyclic compounds as immunomodulators
CY1121938T1 (en) 4-HYDROXY-3-(HETERORYL)PYRIDINO-2-ONE APJ AGENTS FOR USE IN THE TREATMENT OF CARDIAC DISORDERS
NI201600164A (en) COMPOUNDS AND COMPOSITIONS AS AGONISTS OF THE TOLL 7 TYPE RECEPTOR
DOP2016000271A (en) FUSIONED BICYCLIC HETEROARILO OR ARILO COMPOUNDS
CO2017004525A2 (en) Ror-gamma inhibitory dihydropyrrolopyridines
PH12018502307A1 (en) Aromatic sulfonamide derivatives
CL2018002814A1 (en) Compositions and methods for the treatment of wounds, disorders, and skin diseases.
MX2016014308A (en) Compounds and compositions as toll-like receptor 7 agonists.
CL2015002529A1 (en) Tetrahydropyrrolothiazine Compounds
CL2015000880A1 (en) Heterocyclic compounds derived from 4-pyrimidinone, hiv reverse transcriptase inhibitors; pharmaceutical composition; use in the prophylaxis or treatment of hiv infection or for the prophylaxis, treatment or delay of the onset of AIDS in a subject.
UY39706A (en) DERIVATIVES OF (1HINDOL-3-IL)-2-(4-CHLORO-2-METHOXY-PHENYL)-2-((3-METHOXY-5-(METHYLSULFONYL) PHENYL)AMINO)ETHANONE AS INHIBITORS OF THE REPLICATION OF THE VIRUS OF THE DENGUE
UY37182A (en) INDOLINA DERIVATIVES REPLACED AS INHIBITORS OF THE VIRAL REPLICATION OF DENGUE
CL2015001279A1 (en) Compounds derived from pyridine, urate transporter inhibitors urat 1; pharmaceutical composition that includes them; use for the treatment or prevention of diseases such as gout, hyperuricemia, hypertension, kidney diseases, among others.
CL2017001511A1 (en) Piperidine derivatives as hdac1 / 2 inhibitors.
EA201692091A1 (en) CHINOXALINE COMPOUNDS AND THEIR APPLICATION
EA201790519A1 (en) THERAPEUTIC CONNECTIONS AS INTEGRATORS OF OREXIN-1 RECEPTOR
UY37466A (en) N-HYDROXIAMIDINHETEROCICLES SUBSTITUTED AS MODULATORS OF INDOLAMINE 2,3-DIOXYGENASE
EA201890449A1 (en) FUMAGILLINUM HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION AND APPLICATION
CL2015003195A1 (en) Purine derivatives as cb2 receptor agonists.
DOP2016000312A (en) COMPOUNDS DERIVED FROM 1- (CICLOPENT-2-EN-1-IL) -3- (2-HIDROXI-3- (ARILSULFONIL) PHENYL) UREA AS CXCR2 INHIBITORS
UY36145A (en) Compounds of 1, 3, 4-thiadiazole and use thereof for the treatment of cancer
CL2018001085A1 (en) Indolin-2-one derivatives
CU20200038A7 (en) COMPOUNDS DERIVED FROM PYRAZOLO-PIRROLO-PYRIMIDINE-DIONA AS INHIBITORS OF P2X3
CL2016002354A1 (en) Compounds derived from benzamide with wnt inhibitory activity; intermediary compounds; pharmaceutical composition that includes them; use in the treatment of cancer and other diseases with inappropriate immune response.
CL2017000117A1 (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity.